Updated data from the CHRYSALIS-2 study reveals that Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® combination achieves a historic median overall survival of 41.0 months as a first-line therapy for atypical EGFR-mutated advanced non-small cell lung cancer.
Landmark seven-year results from Pfizer’s CROWN study show LORBRENA (lorlatinib) reduces the risk of disease progression or death by 81% in ALK+ NSCLC, setting a new standard for oncology care.
New results from the POSEIDON study presented at the 94th EAS Congress highlight that cardiovascular inflammation risk persists in 40% of high-risk patients, signaling an urgent need for targeted therapies.
Merck has announced that the Phase 3 Trofuse-005 trial evaluating Sacituzumab Tirumotecan (Sac-TMT) successfully met its primary endpoints, offering a new hope for patients with advanced or metastatic NSCLC.
Semaglutide for MASH (Metabolic Dysfunction-associated Steatohepatitis) is poised to change the landscape of hepatology as Novo Nordisk prepares to unveil highly anticipated data at the [Read More…]
Novartis has announced groundbreaking results from the Phase III PSMAddition trial, revealing that Pluvicto significantly reduces the risk of PSA progression by 58% in patients with metastatic hormone-sensitive prostate cancer.
Discover how Wegovy for women delivers substantial weight loss and reduces the risk of migraines and depression across all menopausal stages, according to new Novo Nordisk data.
Novo Nordisk has unveiled groundbreaking clinical sub-analyses at the European Congress on Obesity (ECO) 2026, revealing that high-dose semaglutide (7.2 mg) can lead to nearly 28% weight loss in specific patient groups while preserving vital muscle health.
Johnson & Johnson reinforces its leadership in neuropsychiatry, presenting pivotal data for seltorexant and aticaprant at the 2024 APA and ASCP meetings.
Eli Lilly has released historic long-term data from the Omvoh mirikizumab-mrkz clinical trials, proving that the IL-23p19 antagonist maintains high rates of “disease clearance” through four years of treatment.
